Pyronaridine was synthesized in 1970 at the Institute of Chinese Parasitic Disease and has been used in China for over 30 years for the treatment of malaria.
Plasmodium falciparum is a protozoan parasite that, along with its close relatives, causes malaria in humans.
Previous studies have shown an antimalarial effect of total alkaloids extracted from leaves of Guiera senegalensis from Mali in West Africa.
We conducted this prospective study among 110 symptomatic Plasmodium vivax patients attending the Kasturba Hospital, Manipal, India, in order to evaluate their clinico-laboratory profile during July 2007–July 2009.
In the study, the interaction of CS and TPP and the presence of chloroquine at the surface of chitosan–TPP NPs have been investigated by means of different methods like FTIR, DLS, and zeta potential.
Isolated vesicles from mutant-PfCRT-transformed D. discoideum exhibit features of the CQR phenotype, consistent with evidence that the drug resistance mechanism operates at the P. falciparum digestive vacuole membrane in malaria.
We review some contributions that early efficacy studies of antimalarial treatment brought to clinical pharmacology, including convincing documentation of atebrine-resistant malaria in the 1940s, prior to the launching of what soon became first-choice antimalarials, chloroquine and amodiaquine.
Malaria is still a major threat in many parts of the world with resistance spreading to almost all classes of antimalarials.
Fluoroquinolone analogs were synthesized by simple alkylation followed by click chemistry and evaluated for their antimalarial in vitro against chloroquine sensitive strain of Plasmodium falciparum while ciprofloxacin was used as standard.
This study demonstrated that CYP2C8*2 allele is widespread in Africa.